HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 10/15/2012 -- ChipMOS TECHNOLOG (NASDAQ:IMOS) is very active today and traded between $12.78 - 14.12 with total traded volume of 255221 shares. At a current price of 12.9701, IMOS is -1.0399 - -7.42% from the previous close of $14.01. Moreover, At Current Market Price, IMOS is in distance of -11.18% from its 50-day Moving Average price of $14.6026 and +0.69% from its 200-day Moving Average price of $12.8807.ChipMOS TECHNOLOGIES (Bermuda) LTD announced that it expects consolidated revenue for the fourth quarter of 2012 to be approximately flat to 5% lower, as compared to the third quarter of 2012, reflecting continued growth in its LCD driver and flash memory testing businesses, offset by continued broader softness in the memory market, which is decreasing the Company&aposs commodity DRAM assembly business. The Company reported revenues of NTD5.139 billion in the third quarter 2012.
Can IMOS Find The Top further? Find Out Here
Delcath Systems Inc (NASDAQ:DCTH) decreased 5.0% and the last traded price was $2.09 with a traded volume of 1.81 million shares.The Company had filed ChemoSat liver-tumor treatment system. The FDA refused to accept the company’s new drug application for ChemoSatin early 2011. Delcath finally filed a second approval application for ChemoSat on August 15. Under FDA rules, the agency has 60 days to notify a company about the acceptance of a new drug application seeking priority review. The decision could be announced by October 14.The shares lost 12.92% to $1.82. The US FDA has accepted Delcath Systems&apos New Drug Application for its proprietary chemosaturation system with melphalan hydrochloride for injection.Shares of Delcath Systems Inc. are down 18.66% to $1.70 on trading volume of 2.3 million shares. The company said a drug to help treat liver cancer will receive a standard review by the Food and Drug Administration. The 52-week low is $1.40.
Can DCTH Recover? Check Out Here
Amedisys Inc (NasdaqNM:AMED) reported EPS of -13.90. For the Current Fiscal year, the company is expected to report EPS of 1.01. For the Next Quarter and Next Year, the company is expected to report EPS of 0.26 and 0.93 respectively. At Current Market Price, AMED is in distance of -16.79% from its 50-day Moving Average price of $14.4217 and -8.74% from its 200-day Moving Average price of $13.1493.Amedisys gapped open lower Monday and has continued to fall on above average volume.The stock is now down 1.36 at $11.97 and has dropped to over a 2-month low. Amedisys has also fallen below its 200-day moving average.
How Should Investors React To AMED Now? Click Here
Bassett Furniture (NasdaqNM:BSET) is -0.21 - -1.92% from the previous close of $10.91. It traded between $9.42 - 10.70 with total traded volume of 103940 shares. Keep a close eye on BSET, as the stock has been showing unusual moves over the past weeks. At Current market price, BSET has recovered +51.77% from its 52-week Low of 7.05 and has Pulled back -19.06% from its 52-week high of 13.22.Bassett Furniture Industries, Inc. (Nasdaq:BSET), is a leading manufacturer and marketer of high quality, mid-priced home furnishings. With 86 company- and licensee-owned stores, Bassett has leveraged its strong brand name in furniture into a network of corporate and licensed stores that focus on providing consumers with a friendly environment for buying furniture and accessories. The most significant growth opportunity for Bassett continues to be the Company&aposs dedicated retail store program. Bassett&aposs retail strategy includes affordable custom-built furniture that is ready for delivery in the home within 30 days. The stores also feature the latest on-trend furniture styles, more than 750 upholstery fabrics, free in-home design visits, and coordinated decorating accessories. Bassett is also growing its traditional wholesale business with more than 500 accounts on the open market, across the United States and internationally.
Can BSET Extend Rally? Free sign up here
DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor&aposs entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact:
hotpennystocknews.com
info@hotpennystocknews.com
For more information on this press release visit: http://www.sbwire.com/press-releases/should-trader-buying-this-stocks-right-now-imos-dcth-amed-bset-172277.htm
Media Relations Contact
Souvik Sinha
Email: Click to Email Souvik Sinha
Web: http://hotpennystocknews.com/
No comments:
Post a Comment